5. Catenacci Daniel V, Wainberg Z, Fuchs Charles S, et al. LBA-009KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer. Ann Oncol 2017; 28(suppl_3). 6. Shit...
RESULTS 研究结果 Seventy-seven patients with HTMB with CRC (n=28) or advanced cancers (n=49) were treated with pembrolizumab. For the CRC cohort, the DC rate was 31% (P=.04) and the OR rate was 11%. For the HP cohort, the DC rate was 45% (one-sided 90% CI, 35 to 100) a...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) http://investors.merck.com/news/press-release-details/2017/FDA-Approv...
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A. multicentre, open-label, phase 1b trial. Lancet Oncol. 2016, 17, 717-726. [CrossRef]Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients wit...
1. Health Canada approves Keytruda as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy. News release. Merck Canada. April...
Learn about an immunotherapy treatment option to help certain patients with non–small cell lung cancer. See clinical results here.
帕博利珠单抗(派姆单抗,pembrolizumab,Keytruda)是由默沙东(MSD)公司研发的一款重磅抗PD-1抑制剂,也是中国首个获批上市的PD-1抑制剂。
KEYTRUDA may be used with axitinib as a first treatment when kidney cancer has spread or cannot be removed by surgery. Results from a clinical trial of KEYTRUDA + axitinibLearn about Ed’s TRU story Patients looking for another option KEYTRUDA with another medicine has been studied in patients ...
2024年美国临床肿瘤学会年会(ASCO)上,报告了题为《SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without Pembrolizumab in patients with metastatic hormone receptor-positive/HER2negative breast cancer》...